![Extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial](https://oncodaily.com/pub/uploads/2024/08/IMG_5581.jpeg)
Photo of Nizar M. Tanner taken from mdanderson.org
Aug 7, 2024, 03:03
Extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Daniel Castellano, Medical Oncologist at University Hospital October 12, shared on X:
“Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial – Annals of Oncology.”
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Autors: N.M. Tannir, L. Albigès, D.F. McDermott, M. Burotto, T.K. Choueiri, H.J. Hammers, P. Barthélémy, E.R. Plimack, C. Porta, S. George, F. Donskov, M.B. Atkins, H. Gurney, C.K. Kollmannsberger, M.-O. Grimm, C. Barrios, Y. Tomita, D. Castellano, V. Grünwald, B.I. Rini, R. Jiang, H. Desilva, V. Federov, C.-W. Lee, R.J. Motzer
Source: Daniel Castellano/X
B.I. Rini
C. Barrios
C. Porta
C.-W. Lee
C.K. Kollmannsberger
cancer
D. Castellano
D.F. McDermott
Daniel Castellano
E.R. Plimack
F. Donskov
H. Desilva
H. Gurney
H.J. Hammers
L. Albigès
M. Burotto
M.-O. Grimm
M.B. Atkins
nivolumab
Nizar M. Tannir
OncoDaily
Oncology
P. Barthélémy
R. J. Motzer
R. Jiang
S. George
T. K. Choueiri
V. Federov
V. Grünwald
Y. Tomita
Aug 11, 2024, 08:04
Aug 11, 2024, 07:48
Aug 11, 2024, 06:38
Aug 11, 2024, 05:36